CYP2C19

Gastrointestinal & Hepatic System · Phase I & Phase II Xenobiotic Detoxification

Can CYP2C19 affect how a medicine works?

CYP2C19 makes a liver enzyme used to process multiple medicines. Some drug decisions can depend on a confirmed metabolizer result, but the gene name alone does not specify a dose or a suitable alternative.

Common Gene Name: cytochrome P450 family 2 subfamily C member 19
NCBI Gene ID: 1557
Chromosome: 10

Clinical Evidence Status

Drug-response evidence availableTumor or drug-label biomarker context

These labels describe available evidence about a gene. They do not classify your variant or recommend a treatment.

Answer Sources

Explore supporting evidence (46 records)

Condition or drug	Evidence	Grade / status	Context	Source
Clopidogrel resistance	MedlinePlus related condition	Association type varies; no grade assigned here		View source 2015-12
Abrocitinib	FDA pharmacogenetics	Management recommendation	Drug-specific subgroup	View source
Belzutifan	FDA pharmacogenetics	Management recommendation	Drug-specific subgroup	View source
Brivaracetam	FDA pharmacogenetics	Management recommendation	Drug-specific subgroup	View source
Citalopram	FDA pharmacogenetics	Management recommendation	Drug-specific subgroup	View source
Clobazam	FDA pharmacogenetics	Management recommendation	Drug-specific subgroup	View source
Clopidogrel	FDA pharmacogenetics	Management recommendation	Drug-specific subgroup	View source
Flibanserin	FDA pharmacogenetics	Management recommendation	Drug-specific subgroup	View source
Pantoprazole	FDA pharmacogenetics	Management recommendation	Drug-specific subgroup	View source
Mavacamten	FDA pharmacogenetics	Potential safety or response effect	Drug-specific subgroup	View source
Voriconazole	FDA pharmacogenetics	Potential safety or response effect	Drug-specific subgroup	View source
Carisoprodol	FDA pharmacogenetics	Pharmacokinetics only	Drug-specific subgroup	View source
Dexlansoprazole	FDA pharmacogenetics	Pharmacokinetics only	Drug-specific subgroup	View source
Diazepam	FDA pharmacogenetics	Pharmacokinetics only	Drug-specific subgroup	View source
Doxepin	FDA pharmacogenetics	Pharmacokinetics only	Drug-specific subgroup	View source
Escitalopram	FDA pharmacogenetics	Pharmacokinetics only	Drug-specific subgroup	View source
Esomeprazole	FDA pharmacogenetics	Pharmacokinetics only	Drug-specific subgroup	View source
Lansoprazole	FDA pharmacogenetics	Pharmacokinetics only	Drug-specific subgroup	View source
Omeprazole	FDA pharmacogenetics	Pharmacokinetics only	Drug-specific subgroup	View source
Rabeprazole	FDA pharmacogenetics	Pharmacokinetics only	Drug-specific subgroup	View source
Abrocitinib	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Dermatology	View source
Belzutifan (1)	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Oncology	View source
Brivaracetam	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Neurology	View source
Carisoprodol	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Rheumatology	View source
Citalopram (1)	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Psychiatry	View source
Clobazam	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Neurology	View source
Clopidogrel	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Cardiology	View source
Dexlansoprazole	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Gastroenterology	View source
Diazepam	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Neurology	View source
Doxepin (2)	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Psychiatry	View source
Drospirenone and Ethinyl Estradiol	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Gynecology	View source
Escitalopram (2)	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Psychiatry	View source
Esomeprazole	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Gastroenterology	View source
Flibanserin (2)	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Gynecology	View source
Formoterol (2)	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Pulmonary	View source
Lacosamide	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Neurology	View source
Lansoprazole	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Gastroenterology	View source
Mavacamten	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Cardiology	View source
Omeprazole	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Gastroenterology	View source
Pantoprazole	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Gastroenterology	View source
Phenytoin (2)	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Neurology	View source
Prasugrel (1)	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Cardiology	View source
Rabeprazole	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Gastroenterology	View source
Ticagrelor	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Cardiology	View source
Voriconazole	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Infectious Diseases	View source
Vonoprazan	FDA labeling biomarker	Label mentions biomarker; actionability not inferred	Gastroenterology	View source

Source snapshot: 2026-09-09. Consumer text updated: 2026-09-10. Source dates describe the cited records, not a new clinical review.

← Back to Gastrointestinal & Hepatic System